109733-91-7

Basic information

• Product Name: 1,3-Benzodioxole, 5,5'-methylenebis[6-methyl-
• CAS NO: 109733-91-7
• Molecular Formula: C17H16O4
• Molecular Weight: 284.312
• Mol File: 109733-91-7.mol

Chemical Properties

• CAS DataBase Reference: 1,3-Benzodioxole, 5,5'-methylenebis[6-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Benzodioxole, 5,5'-methylenebis[6-methyl-(109733-91-7)
• EPA Substance Registry System: 1,3-Benzodioxole, 5,5'-methylenebis[6-methyl-(109733-91-7)

Safety Data

• Hazardous Substances Data: 109733-91-7(Hazardous Substances Data)

Upstream product

• 7145-99-5 5-methyl-1,3-benzodioxole 
• 50-00-0 formaldehyd 

Downstream Products

• 33255-24-2 5,5'-dimethyl-4,4'-methanediyl-di-pyrocatechol 
• 1164-05-2 bis-(4,5-dimethoxy-2-methyl-phenyl)-methane 
• 94-53-1 Piperonylic acid 
• 32996-27-3 4,5-methylenedioxy-2-nitrotoluene 

Relevant articles and documents

Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist

Previously we reported the discovery of amidothiophenesulfonamides as endothelin receptor-A antagonists with high potency and selectivity. Replacement of an amide group in this class of compounds with an acetyl group maintained the in vitro binding affinity and in vivo activity while providing a compound with oral bioavailability and longer duration of action. The optimal compound discovered during these studies, 15q (TBC11251), binds competitively to human ET(A) receptors with a K(i) of 0.43 ± 0.03 nM and an IC50 of 1.4 nM (IC50 for ET(B) = 9800 nM). This compound inhibits ET-1- induced stimulation of phosphoinositide turnover with a K(i) of 0.686 nM and a pA2 of 8.0. The compound has a serum half-life in the rat and the dog of 6-7 h and 60-100% oral bioavailability. This compound is one of the most selective ET(A) antagonists reported and therefore is suitable for additional pharmacological and clinical investigation of the role of ET(A) receptors in diseases.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.